ArticleArthroplasty today2026
The Efficacy and Safety of Tranexamic Acid in Revision Total Knee and Total Hip Arthroplasty: A Systematic Review and Meta-Analysis.
Article in Arthroplasty today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study evaluated 3 key aspects of tranexamic acid (TXA) use following revision total hip arthroplasty (rTHA) and revision total knee arthroplasty (rTKA): 1) its efficacy, including changes in hemoglobin, blood loss, blood transfusions, and red blood cell transfusions; 2) its safety, specifically venous thromboembolism including pulmonary embolism and deep vein thrombosis; and 3) the role of TXA administration, including the dose and route. Methods: A comprehensive search was conducted across PubMed, Scopus, Cochrane Cochrane Central Register of Controlled Trials, Embase, and Web of Science through 2024. Studies comparing TXA treatment to non-TXA treatment in patients undergoing rTHA or rTKA were included. Results: Our study included 27 studies with 10,248 patients (4700 in the TXA group and 5548 in the non-TXA group). A total of 25 studies were subjected to meta-analysis. Hemoglobin differences were significantly lower in TXA patients compared to non-TXA patients in both the rTHA (weighted mean difference [WMD] -0.79 g/dl, Conclusions: TXA was found to be effective and safe in both rTHA and rTKA, regardless of administration dose or route.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.